Pharmaceutical Structured Dataset

{
  "drug_id": "DRUG-2025-B8E4V9K2N7",
  "generic_name": "信迪利单抗Injection",
  "generic_name_en": "Sintilimab Injection",
  "brand_names": ["达伯舒","Tyvyt"],
  "approval_number": "国药准字SXXXXXXXX",
  "drug_category": "生物制品",
  "registration_class": "Therapeutic biological products1types（Innovative Drug）",
  "rx_type": "RX（Prescription药）",
  "atc": {"code":"L01FF06","level1":"L 抗Oncology药和Immunology机能调Sec.药","level2":"L01 抗Oncology药","level3":"L01F Monoclonal antibodies and antibody-drug conjugates","level4":"L01FF PD-1/PD-L1抑Formulation","level5":"L01FF06 sintilimab"},
  "dosage_form": "Injection剂",
  "strength": "10ml:100mg",
  "route": "Intravenous输注",
  "indications": {
    "approved": ["Classical HodgkinLymph瘤（After at least second-line systemic chemotherapy）","Non-squamous non-small cell lung cancer（联合培美曲塞+铂types）","Hepatocellular carcinoma（Combined with bevacizumab biosimilar）"],
    "icd_codes": ["2B30.0","2C25.0","2C12.02"]
  },
  "administration": {"adult_usual":"200mg，Intravenous输注30-60min钟，每3周1times","max_daily":"200mg/times"},
  "adverse_effects": {"common":["Fever","Fatigue","Rash","Thyroid功能减退","ALT/ASTElevated"],"serious":["ImmunologyRelevance肺炎","ImmunologyRelevance肝炎","ImmunologyRelevance心肌炎","输注相关反应"]},
  "contraindications": ["Patients allergic to the active ingredient or any excipients"],
  "pharmacology": {"class":"PD-1ImmunologyExamination点抑Formulation","mechanism":"Recombinant fully human antiPD-1单克隆抗体，阻断PD-1与PD-L1/PD-L2结合，RestoreT细胞抗OncologyImmunology应答","target":"PD-1 (CD279)"},
  "clinical_trials": [
    {"ctr_number":"CTRXXXXXXXX","phase":"III","indication":"Non-squamous non-small cell lung cancer","status":"Completed","sponsor":"信达生物制药","enrollment":397}
  ],
  "manufacturer": {"name":"信达生物制药（Suzhou）Co., Ltd.","mah":"信达生物制药"},
  "version": "2025Q2",
  "quality_score": 98.8
}

{
  "drug_id": "DRUG-2025-Z8C5Y3M1N2",
  "generic_name": "连花清瘟Capsule",
  "brand_names": ["连花清瘟","Lianhua Qingwen"],
  "approval_number": "国药准字ZXXXXXXXX",
  "drug_category": "Chinese Patent Medicine",
  "rx_type": "OTC（甲types）",
  "tcm_properties": {"nature":"寒","flavor":"苦、辛","meridian_tropism":["肺","Stomach"]},
  "dosage_form": "Capsule剂",
  "specification": "每粒装0.35g",
  "route": "Oral",
  "ingredients": ["Forsythia","金银花","炙麻黄","炒苦杏仁","石膏","板蓝根","绵马贯众","鱼腥草","广藿香","大黄","红景天","薄荷脑","Licorice"],
  "indications": {
    "approved": ["清瘟解毒，宣肺泄热。Indicated for influenza with heat-toxin attacking the lung pattern (TCM)，症见Fever或高热、恶寒、Muscle酸痛、鼻塞流涕、Cough、Headache、咽干咽痛、舌偏红、Yellow or greasy tongue coating。"],
    "icd_codes": ["1E30"]
  },
  "administration": {"adult_usual":"一times4粒，一day3times"},
  "adverse_effects": {"common":["StomachIntestine道不适","Nausea","Diarrhea"],"rare":["Rash"]},
  "contraindications": ["风寒感冒者Not Applicable","Contraindicated in patients allergic to this product"],
  "manufacturer": {"name":"Shijiazhuang以岭药业股recordsCo., Ltd."},
  "package_insert_update": "2023-04-01",
  "version": "2025Q2",
  "quality_score": 97.5
}

{
  "drug_id": "DRUG-2025-A5R2T8W4N6",
  "generic_name": "头孢呋辛酯片",
  "generic_name_en": "Cefuroxime Axetil Tablets",
  "brand_names": ["西力欣","Zinnat"],
  "approval_number": "国药准字HXXXXXXXX",
  "drug_category": "Chemical Drug品",
  "registration_class": "化药4types",
  "rx_type": "RX（Prescription药）",
  "atc": {"code":"J01DC02","level1":"J 全身用抗Infection药","level2":"J01 全身用抗菌药","level3":"J01D Otherβ-Beta-lactam antibacterial","level4":"J01DC Second-generation cephalosporin","level5":"J01DC02 cefuroxime"},
  "dosage_form": "薄膜衣片",
  "strength": "0.25g（按C16H16N4O8S计）",
  "route": "Oral",
  "is_antibiotic": true,
  "antibacterial_spectrum": "Second-generation cephalosporin，对G+球菌和PartG-杆菌有效，对β-内酰胺酶Stable",
  "indications": {
    "approved": ["Acute咽炎/扁桃体炎","Acute中耳炎","AcuteBacterial sinusitis","ChronicBronchus炎Acute发作","单纯性尿Rd.Infection","单纯性Dermatology和软OrganizationInfection"],
    "icd_codes": ["CA02.0","AB00.1","CA02","CA22.1","GC08.0"]
  },
  "administration": {"adult_usual":"0.25g，每day2times（q12h）","child":"按体重20-30mg/kg/day，min2times","timing":"Take after meals to increase absorption"},
  "adverse_effects": {"common":["Diarrhea","Nausea","Vomiting","Rash"],"serious":["伪膜性Intestine炎","过敏性休克（罕见）"]},
  "interactions": [
    {"drug":"Oral抗凝药（华法林）","severity":"MonitoringINR","mechanism":"可能Enhancement抗凝效果"}
  ],
  "contraindications": ["Patients allergic to cephalosporins or penicillins","Patients with history of immediate hypersensitivity to penicillins"],
  "pharmacology": {"class":"Cephalosporin antibiotics（第二代）","mechanism":"PassBinds to bacterial penicillin-bindingProtein（PBPs）结合，Inhibits bacterial cell wall synthesis","microbiology":{"mssa":"S","streptococcus_pneumoniae":"S","h_influenzae":"S","moraxella":"S","e_coli":"S","pseudomonas":"R"}},
  "manufacturer": {"name":"葛兰素史克（GSK）","mah":"GlaxoSmithKline"},
  "version": "2025Q2",
  "quality_score": 98.5
}

{
  "drug_id": "DRUG-2025-C6N4X8F2K7",
  "generic_name": "Nifedipine Controlled-Release Tablets",
  "generic_name_en": "Nifedipine Controlled-release Tablets",
  "brand_names": ["拜新同","Adalat GITS"],
  "approval_number": "国药准字HXXXXXXXX",
  "drug_category": "Chemical Drug品",
  "registration_class": "化药4types",
  "rx_type": "RX（Prescription药）",
  "atc": {"code":"C08CA05","level1":"C CardiovascularSystem","level2":"C08 Calcium channel blocker","level3":"C08C Selective calcium channel blocker primarily acting on blood vessels","level4":"C08CA Dihydropyridine derivative","level5":"C08CA05 nifedipine"},
  "dosage_form": "控释片",
  "strength": "30mg",
  "route": "Oral",
  "dosage_technology": "Osmotic pump controlled-release system（GITS），Zero-order release kinetics",
  "indications": {"approved":["原发性高Blood Pressure","ChronicStable型心绞痛（劳力性心绞痛）","变异型心绞痛"],"icd_codes":["BA00","BA40","BA41"]},
  "administration": {"adult_usual":"30mg，每day1times","max_daily":"60mg","timing":"整片吞服，不可掰开、嚼碎","caution":"For hepatic impairment, start from30mg起始"},
  "adverse_effects": {"common":["Headache","面部潮红","踝部Edema","Dizziness","Fatigue"],"serious":["严重低Blood Pressure","心绞痛Exacerbation（罕见）"]},
  "interactions": [
    {"drug":"CYP3A4强效抑Formulation（伊曲康唑、克拉霉素）","severity":"禁忌","mechanism":"Significantly increases nifedipinePlasma Drug Concentration"},
    {"drug":"葡萄柚汁","severity":"避免","mechanism":"抑制CYP3A4，ElevatedPlasma Drug Concentration"}
  ],
  "contraindications": ["心源性休克","不Stable心绞痛（发作期）","Acute心肌梗死（4周内）","妊娠20周within"],
  "pharmacology": {"class":"Dihydropyridine calcium channel blocker","mechanism":"Select性阻断L型钙通道，扩sheets外周Intra-arterial和Coronary Artery","pk":{"tmax_h":6,"half_life_h":7,"bioavailability":"45-75%（LiverFirst-Pass Effect）"}},
  "manufacturer": {"name":"拜耳PharmaceuticalsHealthcareCo., Ltd.","country":"Germany"},
  "version": "2025Q2",
  "quality_score": 99.0
}